Ostrowski Erik
Known title: SVP, CFO, CBO & TreasurerCIK: 0001762507
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
TECX Reports Positive Phase 1 Data for TX2100 in HHT. Tectonic Therapeutic released results from its Phase 1 study of TX2100, a treatment aimed at hereditary hemorrhagic telangiectasia. The data showed the drug was safe, well tolerated and demonstrated expected pharmacokinetic behavior. These early findings support continued development of the candidate. The news arrives while the stock is trading near a long‑term support level.
Transaction History
| AKBA | ▼ Sell | Open Market | 56,019 | $62K | 6/29/2026 | View on chart |
| AKBA | ▼ Sell | Open Market | 34,951 | $49K | 2/2/2026 | View on chart |
| AKBA | ▲ Buy | Grant | 204,000 | $0 | 1/30/2026 | View on chart |
| AKBA | ▼ Sell | Open Market | 41,314 | $152K | 6/30/2025 | View on chart |
| AKBA | ▲ Buy | Grant | 194,900 | $0 | 1/31/2025 | View on chart |
| AKBA | ▲ Buy | Grant | 350,000 | $0 | 6/28/2024 | View on chart |
| TECX | ▼ Sell | Tax Withholding | 13,099 | $16K | 2/5/2024 | View on chart |
| TECX | ▲ Buy | Option Exercise | 40,084 | $0 | 2/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
AKBA sees no direct news updates this week
In the past week, there were no company‑specific announcements for Akebia Therapeutics (AKBA). The only notable filing was SCYNEXIS appointing Dr. Steven K. Burke to its board, which does not involve AKBA. As a result, there is little new information to affect AKBA’s market perception at this time.
AKBA sees no direct news updates this week. In the past week, there were no company‑specific announcements for Akebia Therapeutics (AKBA). The only notable filing was SCYNEXIS appointing Dr. Steven K. Burke to its board, which does not involve AKBA. As a result, there is little new information to affect AKBA’s market perception at this time.